Dr. Ashley E. Frith, MD
Medical Oncology (Medical Oncology Physician)
150 Entrance Way, Div Im Medical Oncology, Ste 100
Saint Peters, MO 63376
Who else practices at this address →
St. Charles County is a federal mental health shortage area; it also includes dental (16% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Arkansas College of Medicine (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 466
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: University of Arkansas College of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MO license 2013021417
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Barnes Jewish Hospital Saint Louis, MO
- Missouri Baptist Medical Center Saint Louis, MO
- Barnes-Jewish West County Hospital Creve Coeur, MO
- Barnes-Jewish St Peters Hospital Saint Peters, MO
- Progress West Hospital Ofallon, MO
Medical groups
- Washington University (3,029 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 466
- Services billed
- 94,647
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 21,300 | 12 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 18,660 | 13 |
| Injection, fosaprepitant, 1 mg | 12,000 | 38 |
| Injection, azacitidine, 1 mg | 10,900 | 11 |
| Injection, pembrolizumab, 1 mg | 10,600 | 19 |
| Injection, denosumab, 1 mg | 7,260 | 42 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 5,400 | 15 |
| Injection, paclitaxel, 1 mg | 4,377 | 12 |
| Injection, docetaxel, 1 mg | 4,118 | 16 |
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 3,780 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 36 payments worth $2,991 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $1,976 |
|---|---|
| Daiichi Sankyo Inc. | $292 |
| Gilead Sciences, Inc. | $237 |
| Lilly USA, LLC | $218 |
| E.r. Squibb & Sons, L.l.c. | $122 |
| Stemline Therapeutics Inc. | $100 |
| Sumitomo Pharma America, Inc. | $23.30 |
| Merck Sharp & Dohme LLC | $23.27 |
| Consulting Fee | $1,360 |
|---|---|
| Food and Beverage | $1,228 |
| Travel and Lodging | $403 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Aug 26, 2025 | Consulting Fee | $1,360 |
| AstraZeneca Pharmaceuticals LP Oct 24, 2025 | Travel and Lodging travel to Denver, CO · in-kind Company’s descriptionConsulting Expenses | $323 |
| AstraZeneca Pharmaceuticals LP Oct 24, 2025 | Travel and Lodging travel to Denver, CO · in-kind Company’s descriptionConsulting Expenses | $79.58 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $834,161 in research payments for these studies, mostly to the institutions running them.
- A phase 1B2 openlabel study of disitamab vedotin in combination with other anticancer therapies in solid tumors
Pfizer Inc. - Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292.
AstraZeneca Pharmaceuticals LP - Randomized doubleblind phase 3 study of tucatinib or placebo in combination with adotrastuzumab emtansine TDM1 for subjects with unresectable locallyadvanced or metastatic HER2 breast cancer HER2CLIMB02
Pfizer Inc. - DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Daiichi Sankyo Inc. · Completed · NCT03523585 - A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)
Daiichi Sankyo Inc. · Terminated · NCT03248492 - A phase 1B2 dose escalation and expansion study of tucatinib in combination with trastuzumab and oxaliplatinbased chemotherapy or pembrolizumabcontaining combinations for HER2 gastrointestinal cancers
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.